Lake Street Capital Issues Positive Forecast for Personalis (NASDAQ:PSNL) Stock Price

Personalis (NASDAQ:PSNL) had its price objective upped by analysts at Lake Street Capital from $7.00 to $9.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s target price points to a potential upside of 68.22% from the stock’s previous close.

Several other research analysts have also recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $7.25 target price on shares of Personalis in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Personalis in a report on Wednesday.

Personalis Trading Down 10.5 %

Shares of NASDAQ:PSNL traded down $0.63 during trading on Wednesday, reaching $5.35. 874,950 shares of the stock were exchanged, compared to its average volume of 929,288. Personalis has a 12 month low of $1.12 and a 12 month high of $7.20. The stock has a 50-day moving average price of $4.68 and a 200-day moving average price of $4.31. The firm has a market cap of $377.97 million, a PE ratio of -3.18 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The firm had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same period in the prior year, the company earned ($0.51) earnings per share. On average, sell-side analysts expect that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC boosted its position in Personalis by 6.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock worth $1,237,000 after buying an additional 66,128 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after purchasing an additional 4,504 shares during the period. nVerses Capital LLC bought a new stake in shares of Personalis in the third quarter worth $40,000. International Assets Investment Management LLC increased its holdings in Personalis by 438.0% in the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after purchasing an additional 17,082 shares during the period. Finally, Semanteon Capital Management LP bought a new position in Personalis during the 3rd quarter worth $375,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.